Moderna: Unterschied zwischen den Versionen
| [gesichtete Version] | [gesichtete Version] |
Thomas (Diskussion | Beiträge) |
FreeW (Diskussion | Beiträge) |
||
| (Eine dazwischenliegende Version desselben Benutzers wird nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| − | [https://www.modernatx.com/ | + | [https://www.modernatx.com/ Webseite] |
| − | === Corona Impfstoff === | + | === [[RNA-Impfstoff|Corona-Impfstoff]] === |
| − | Moderna ist Hersteller eines Corona-Impfstoffes | + | Moderna ist Hersteller eines [[Corona|Corona]]-Impfstoffes |
[https://www.pei.de/DE/newsroom/hp-meldungen/2021/210106-ema-empfiehlt-bedingte-zulassung-covid-19-impfstoff-moderna.html;jsessionid=87D3D876516E9BC0CCF98E0F2B596F13.intranet241 Ausschuss für Humanarzneimittel CHMP empfiehlt bedingte Zulassung für den COVID-19-Impfstoff von Moderna] Pressemitteilung des [[Paul-Ehrlich-Institut|Paul-Ehrlich-Instituts]]. Aktualisiert 6.1.2021 | [https://www.pei.de/DE/newsroom/hp-meldungen/2021/210106-ema-empfiehlt-bedingte-zulassung-covid-19-impfstoff-moderna.html;jsessionid=87D3D876516E9BC0CCF98E0F2B596F13.intranet241 Ausschuss für Humanarzneimittel CHMP empfiehlt bedingte Zulassung für den COVID-19-Impfstoff von Moderna] Pressemitteilung des [[Paul-Ehrlich-Institut|Paul-Ehrlich-Instituts]]. Aktualisiert 6.1.2021 | ||
| Zeile 12: | Zeile 12: | ||
{{Quote|The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.}} | {{Quote|The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.}} | ||
| − | [[Category:COVID19 Impfstoffhersteller]] [[Category: | + | == Siehe auch == |
| + | |||
| + | 🔥 [[Corona_/_Corona-Katastrophe_/_Corona-Krise_/_COVID-19-Pandemie#Impfung_-_Impfindustrie.2C_Impfkritik.2C_Impfpflicht.2C_Impfstoff.2C_Impfzwang.2C_Zwangsimpfung|Impfung - Impfindustrie, Impfkritik, Impfpflicht, Impfstoff, Impfzwang, Zwangsimpfung]] | ||
| + | |||
| + | [[Category:COVID19 Impfstoffhersteller]] [[Category:Impfstoffhersteller]] | ||
| + | [[Category:Pharmazieunternehmen]] [[Kategorie:NOCH ZU BEARBEITEN]] | ||
Aktuelle Version vom 10. Juli 2024, 00:10 Uhr
Corona-Impfstoff
Moderna ist Hersteller eines Corona-Impfstoffes
Ausschuss für Humanarzneimittel CHMP empfiehlt bedingte Zulassung für den COVID-19-Impfstoff von Moderna Pressemitteilung des Paul-Ehrlich-Instituts. Aktualisiert 6.1.2021
Auszug aus dem Disclaimer einer Mitteilung für Investoren:
The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the fact that the safety and efficacy of mRNA-1273 has not yet been established; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
Siehe auch
🔥 Impfung - Impfindustrie, Impfkritik, Impfpflicht, Impfstoff, Impfzwang, Zwangsimpfung
